Literature DB >> 23423978

Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

Suresh Kalathil1, Amit A Lugade, Austin Miller, Renuka Iyer, Yasmin Thanavala.   

Abstract

The extent to which T-cell-mediated immune surveillance is impaired in human cancer remains a question of major importance, given its potential impact on the development of generalized treatments of advanced disease where the highest degree of heterogeneity exists. Here, we report the first global analysis of immune dysfunction in patients with advanced hepatocellular carcinoma (HCC). Using multi-parameter fluorescence-activated cell sorting analysis, we quantified the cumulative frequency of regulatory T cells (Treg), exhausted CD4(+) helper T cells, and myeloid-derived suppressor cells (MDSC) to gain concurrent views on the overall level of immune dysfunction in these inoperable patients. We documented augmented numbers of Tregs, MDSC, PD-1(+)-exhausted T cells, and increased levels of immunosuppressive cytokines in patients with HCC, compared with normal controls, revealing a network of potential mechanisms of immune dysregulation in patients with HCC. In dampening T-cell-mediated antitumor immunity, we hypothesized that these processes may facilitate HCC progression and thwart the efficacy of immunotherapeutic interventions. In testing this hypothesis, we showed that combined regimens to deplete Tregs, MDSC, and PD-1(+) T cells in patients with advanced HCC restored production of granzyme B by CD8(+) T cells, reaching levels observed in normal controls and also modestly increased the number of IFN-γ producing CD4(+) T cells. These clinical findings encourage efforts to restore T-cell function in patients with advanced stage disease by highlighting combined approaches to deplete endogenous suppressor cell populations that can also expand effector T-cell populations. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423978      PMCID: PMC3645275          DOI: 10.1158/0008-5472.CAN-12-3381

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.

Authors:  Kalathil Suresh; Graeme Fraser; Elizabeth Scheid; Brian Leber; Jack Gauldie; Ronan Foley
Journal:  Leuk Lymphoma       Date:  2006-02

2.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

3.  Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.

Authors:  Camille Laurent; Sabina Müller; Catherine Do; Talal Al-Saati; Sophie Allart; Luigi Maria Larocca; Stefan Hohaus; Sophie Duchez; Anne Quillet-Mary; Guy Laurent; Pierre Brousset; Salvatore Valitutti
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

4.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

Authors:  Noritoshi Kobayashi; Nobuyoshi Hiraoka; Wataru Yamagami; Hidenori Ojima; Yae Kanai; Tomoo Kosuge; Atsushi Nakajima; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

8.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Authors:  Chien-Ying Liu; Yu-Min Wang; Chih-Liang Wang; Po-Hao Feng; How-Wen Ko; Yun-Hen Liu; Yi-Cheng Wu; Yen Chu; Fu-Tsai Chung; Chih-Hsi Kuo; Kang-Yun Lee; Shu-Min Lin; Horng-Chyuan Lin; Chun-Hua Wang; Chih-Teng Yu; Han-Pin Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

9.  Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma.

Authors:  Silvia Della Bella; Stefania Nicola; Lucia Brambilla; Antonio Riva; Silvia Ferrucci; Pietro Presicce; Vinicio Boneschi; Emilio Berti; Maria Luisa Villa
Journal:  Clin Immunol       Date:  2006-03-09       Impact factor: 3.969

10.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968

View more
  98 in total

Review 1.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cancer Immunol Immunother       Date:  2016-02-24       Impact factor: 6.968

Review 2.  Immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Christopher E Jensen; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes
Journal:  Hepat Oncol       Date:  2016-06-27

3.  IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.

Authors:  Q Yang; X Li; H Chen; Y Cao; Q Xiao; Y He; J Wei; J Zhou
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

4.  Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib.

Authors:  Suresh Gopi Kalathil; Amit Anand Lugade; Renuka Iyer; Austin Miller; Yasmin Thanavala
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

5.  Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.

Authors:  Su Jong Yu; Chi Ma; Bernd Heinrich; Zachary J Brown; Milan Sandhu; Qianfei Zhang; Qiong Fu; David Agdashian; Umberto Rosato; Firouzeh Korangy; Tim F Greten
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

6.  Endoplasmic reticulum stress induced LOX-1 CD15+ polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma.

Authors:  Jiang Nan; Yan-Fang Xing; Bo Hu; Jian-Xin Tang; Hui-Min Dong; Yu-Mei He; Dan-Yun Ruan; Qing-Jian Ye; Jia-Rong Cai; Xiao-Kun Ma; Jie Chen; Xiu-Rong Cai; Ze-Xiao Lin; Xiang-Yuan Wu; Xing Li
Journal:  Immunology       Date:  2017-12-21       Impact factor: 7.397

7.  A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

Authors:  Qunfeng Wu; Liya Pi; Thu Le Trinh; Chaohui Zuo; Man Xia; Yu Jiao; Zhouhua Hou; Sung Jo; William Puszyk; Kien Pham; David R Nelson; Keith Robertson; David Ostrov; Pranela Rameshwar; Chang Qing Xia; Chen Liu
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

Review 8.  Myeloid cells in hepatocellular carcinoma.

Authors:  Shanshan Wan; Ning Kuo; Ilona Kryczek; Weiping Zou; Theodore H Welling
Journal:  Hepatology       Date:  2015-07-01       Impact factor: 17.425

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

10.  Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Yunyu Chen; James B Wing; Silke Paust; Jonathan M Levitt; William K Decker
Journal:  Stem Cells Dev       Date:  2016-05-02       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.